Pr Robbert van der Most, PhD, CEA of VaxxCellence, independent consultancy company Belgium

Robbert received his PhD in virology at the University of Leiden in 1994. After postdoctoral work on LCMV immunology, human immunology using  YFV-17D immunization as a model and immune-oncology, he joined GSK Vaccines in 2008, leading the Translational Science team, focusing on malaria, TB, influenza and others. He left GSK in 2021, joined CEPI and then worked at BioNTech from 2022 till 2024 as head of translational science for infectious diseases and built the team to manage the portfolio of projects. After leaving BioNTech, Robbert started his own consultancy company and currently works as an independent consultant.